The short version
If sex, desire or intimacy feels different after cancer treatment, you are in large company, and there is usually someone who can help. Cancer Council and Macmillan both say cancer and its treatment can affect the sex organs, sex drive, sexual function and body image, and that some changes are temporary while others last. Many changes can be managed, and the first step is saying it out loud to a member of your care team.
This guide is for people treated for breast, prostate, gynaecological, bowel and other cancers, and for their partners. It covers why treatment changes sexual function, who to ask, what is known about common remedies (including where the evidence is mixed), and the symptoms that need a medical call. Claim strength is labelled STRONG, MODERATE, EMERGING, CONTESTED or UNEVIDENCED. It is educational information, not individual medical advice, and nothing here should be tried before your treating team has said it is safe for you.
Why treatment changes sexual function
There is rarely one cause. The National Cancer Institute (NCI) lists several. Pelvic surgery can affect nerves, and nerve-sparing surgery is used in some cases to try to prevent that. Radiation to the pelvis can damage blood vessels or nerves and, in women, can lower oestrogen and cause vaginal dryness, narrowing (stenosis) and thinning of tissue. Chemotherapy can lower oestrogen and cause ovarian insufficiency. Hormone therapy lowers sex hormones, which in men can reduce testosterone and sex drive and make erections harder to get or keep. NCI adds that medicines for pain or depression, and conditions such as heart disease, high blood pressure, diabetes and smoking, can also contribute.
Body image sits alongside the physical causes. NCI notes that physical changes, such as after a mastectomy or an ostomy, may affect how you see your body, and Cancer Council says a diagnosis can affect relationships as well as function. Fatigue, pain, mood and worry about a partner's reaction also feed into desire.
A 2026 narrative review of sexual dysfunction after cancer (abstract) reports that women more often have less visible difficulties such as reduced desire and painful sex, while men more often have overt erection or ejaculation problems. That is a pattern, not a prediction.
Who to ask
Start with the team you already have. Macmillan suggests your GP or practice nurse, cancer doctor, specialist nurse, local sexual health service or therapeutic radiographer, and notes referrals can go to a urologist, gynaecologist, physiotherapist, endocrinologist or sex therapist. Cancer Council also lists psychologists, social workers, cancer care coordinators and sexual health physicians. Pelvic-floor physiotherapists and psycho-oncology services (psychological care within cancer services) are other routes where available.
The American Society of Clinical Oncology (ASCO) guideline (adapted from a Cancer Care Ontario guideline) recommends that a member of the health care team start a conversation about sexual health, that psychosocial or psychosexual counselling be offered to all patients with cancer, and that treatable medical contributors be addressed first. In practice, teams do not always raise it. The American Cancer Society page notes that many doctors and nurses do not know the right questions to ask, so you may need to start the conversation yourself. Macmillan's advice is not to let embarrassment stop you.
Helplines: Cancer Council on 13 11 20 (Australia), Macmillan on 0808 808 00 00, 8am to 8pm, seven days (UK), and the American Cancer Society on 1-800-227-2345, available 24 hours (US). These are information and support lines, not a substitute for your own team.
Vaginal dryness, pain and dilators
Dryness and discomfort are among the most common concerns after treatment that lowers oestrogen. Macmillan distinguishes lubricants (applied before or during sex) from moisturisers (applied regularly to draw moisture into the vaginal walls), notes that oil-based products can damage latex condoms, and says vaginal oestrogen is not suitable for everyone or after some cancers. The ASCO guideline summary says lubricants and moisturisers may be tried first, with low-dose vaginal oestrogen, lidocaine or DHEA considered in some cases. Whether any hormone-containing product is appropriate after a hormone-sensitive cancer is a decision for your oncologist, not something to settle yourself. Evidence label for lubricants and moisturisers as first-line options: guideline-endorsed, MODERATE.
Dilators are different. Macmillan describes teams giving them to help prevent narrowing after pelvic radiotherapy, and Cancer Research UK says use can start from 2 to 8 weeks after treatment, with timing to be confirmed with your team. The Cochrane review (Miles and Johnson, 2014) found no trials that met its criteria. It states there is no evidence to support dilation during radiotherapy, that observational links between frequent dilation and less narrowing may reflect healthier tissue making it easier to comply, and that women who want to preserve vaginal length after radiotherapy should consider dilation. Macmillan says there is no strong evidence about effectiveness and that, rarely, dilators can damage the vagina if not used correctly. Evidence label: UNEVIDENCED by trials, but widely recommended in practice. Only use a dilator under your radiotherapy team's instructions.
Erections, orgasm and penile rehabilitation
After prostate or other pelvic treatment, erection problems are common, and NCI notes that if the prostate is damaged you may have a dry orgasm. The ASCO guideline says men may benefit from phosphodiesterase type 5 (PDE5) inhibitors, with surgery (such as an implant) an option when symptoms do not respond to medical management.
"Penile rehabilitation" means using medicines or devices early, on a schedule, in the hope of protecting erectile function after surgery. The evidence is honestly mixed. A 2018 Cochrane review (Philippou and colleagues; 8 trials, 1,699 men) concluded that scheduled PDE5 inhibitors may not improve self-reported potency or erectile function any more than on-demand use, rated the quality of evidence very low for most main outcomes, and found no data beyond 12 months. A 2021 systematic review found PDE5 inhibitor results in humans contradictory and evidence for non-drug options scarce, and a 2026 umbrella review (abstract) described the overall evidence as weak while noting penile prostheses show high satisfaction. A 2026 systematic review of 12 trials of pelvic-floor muscle training (abstract) found inconsistent benefit, with four trials significant and seven not. Evidence label for any rehabilitation protocol: CONTESTED.
None of that says treatment is pointless. It means the decision is individual and should be made with your urologist, who can tell you what is safe for your surgery and health. If you are in a relationship, raise orgasm and intimacy as well as erections.
Body image, desire and talking with a partner
Many people avoid closeness for fear it will be expected to lead to sex; talking with a partner about other ways to be intimate is a commonly suggested step. Macmillan likewise says you should not feel pressure to be sexually active. That gives permission to separate three things that often get tangled: closeness, pleasure and intercourse.
Evidence for formal couple and counselling programmes is modest. A 2025 randomised trial of a four-session telephone couple intervention for breast cancer survivors (Reese and colleagues, abstract) found short-term improvements in the survivors' sexual function but minimal effects at three and six months. A 2026 meta-analysis of model-based sexual counselling in breast cancer (abstract) found significant effects on sexual function but rated certainty very low, and PLISSIT-based counselling showed no significant effect. Evidence label: EMERGING.
A partner may be processing fear or grief too and can need support of their own.
Mindfulness and sensate-focus approaches: what the trials show
Mindfulness-based approaches are the best-studied non-medical option for women, and the research is mostly from Lori Brotto's group. A 2008 pilot of a three-session psychoeducational programme with mindfulness training in 22 women treated for cervical or endometrial cancer (abstract) reported improvements in desire, arousal, orgasm, satisfaction and distress, and women rated the mindfulness component most helpful. A 2012 randomised trial of 31 survivors (abstract) compared three 90-minute sessions of mindfulness-based cognitive behavioural therapy with a wait-list and found the intervention improved all domains of sexual response, though sexual distress showed only a trend, and the authors note limited generalisability. A 2017 online programme study (abstract) found gains for women that held at six months but, for men, no significant change in desire.
Newer, larger trials are more sobering. A 2024 randomised trial in breast cancer survivors (abstract) compared online mindfulness-based group sex therapy with supportive group sex education, and both improved desire, distress and vaginal pain with no difference between arms. A 2025 trial of an online support group for 398 women treated for gynaecological cancer (abstract) found no significant difference in the primary outcome, sexual distress, and sexual function gains were not retained at four months, and the authors describe it as underpowered. A 2025 meta-analysis of 12 trials (abstract) found every trial reported improvement in at least one domain, with the largest effects in single-arm studies, and concluded that more rigorous trials are needed. Evidence label: EMERGING, mainly for women, with an unresolved question of whether the benefit is specific to mindfulness or shared with any supportive education.
Sensate focus (structured, graded, non-goal-oriented touch) is widely used in sex therapy, and our sensate-focus guide covers it. We searched and found no cancer-specific controlled trials of sensate focus alone, so we label it UNEVIDENCED in this population. Contemplative and somatic practices whose mechanisms overlap with mindfulness, breath and sensate-focus approaches may suit some people as an adjunct, but they do not repair tissue or treat a medical cause. Do not begin any practice involving touch, breath work or pelvic muscles until your treating team has cleared you.
When to see a professional
Contact your cancer team or GP promptly for bleeding. Macmillan says to always tell your team or GP if the vaginal walls bleed after pelvic radiotherapy, and Cancer Research UK says to contact a health professional for a lot of bleeding or pain, while a small amount of bleeding can be usual early on. Pain during sex, new or worsening pain elsewhere in the pelvis, thrush symptoms that do not settle or keep returning, and unexplained vaginal discharge are all worth raising.
Fever, new swelling, severe pain or trouble passing urine after treatment are not symptoms to manage with a guide. We did not find a source that lists them for sexual problems specifically, so ask your cancer team in advance who to ring, including after hours, and use your local emergency service if you are seriously unwell. NCI also notes some periods of treatment may call for avoiding sex because of infection or bleeding risk, so confirm timing with your doctor.
If low mood, hopelessness or thoughts of self-harm are present, treat that as the priority: tell your team or GP, and if you are in immediate danger contact your local emergency number or crisis line. Cancer Council's 13 11 20 line can also point you to support. If distress feels overwhelming, call Lifeline on 13 11 14 in Australia, Samaritans on 116 123 in the UK, or 988 in the US; in an emergency call 000, 999 or 911.
What this guide does not cover
This guide does not cover fertility and contraception, sexual practices for people on specific treatments, or individual treatment decisions, and it is not a substitute for advice from your oncology team. We did not find a verified, citable source for how many people in each cancer type are affected, so we have left prevalence figures out rather than guess. Evidence on same-sex couples, trans and gender-diverse people and men is thinner than for heterosexual women with breast or gynaecological cancer, and several of the trials above enrolled mostly women. If you do not see yourself in the research, that is a gap in the research and not evidence that help does not exist. The American Cancer Society page notes that sharing your orientation, gender and any hormones with your team helps them tailor care.